APIMEDS PHARMACEUTICALS US I (APUS) Stock Price, Forecast & Analysis

NYSEARCA:APUS • US03771D1028

1.23 USD
+0.13 (+11.82%)
At close: Feb 13, 2026
1.1712 USD
-0.06 (-4.78%)
After Hours: 2/13/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

APUS Key Statistics, Chart & Performance

Key Statistics
Market Cap15.47M
Revenue(TTM)N/A
Net Income(TTM)-1.39M
Shares12.58M
Float3.09M
52 Week HighN/A
52 Week LowN/A
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.12
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPO2025-05-09
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
APUS short term performance overview.The bars show the price performance of APUS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

APUS long term performance overview.The bars show the price performance of APUS in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of APUS is 1.23 USD. In the past month the price decreased by -28.9%.

APIMEDS PHARMACEUTICALS US I / APUS Daily stock chart

APUS Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
APUS Full Technical Analysis Report

APUS Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to APUS. No worries on liquidiy or solvency for APUS as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
APUS Full Fundamental Analysis Report

APUS Financial Highlights

Over the last trailing twelve months APUS reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS decreased by -78.72% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -13.18%
ROE -14.27%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)-78.72%
Revenue 1Y (TTM)N/A
APUS financials

APUS Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
APUS Analyst EstimatesAPUS Analyst Ratings

APUS Ownership

Ownership
Inst Owners3.18%
Ins Owners13.29%
Short Float %0.43%
Short Ratio0.11
APUS Ownership

APUS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.94402.079B
AMGN AMGEN INC16.38197.191B
GILD GILEAD SCIENCES INC17.38188.348B
VRTX VERTEX PHARMACEUTICALS INC24.11117.985B
REGN REGENERON PHARMACEUTICALS17.2982.362B
ALNY ALNYLAM PHARMACEUTICALS INC46.9340.753B
INSM INSMED INC N/A31.174B
BIIB BIOGEN INC12.9228.692B
NTRA NATERA INC N/A28.683B
UTHR UNITED THERAPEUTICS CORP16.0720.502B

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges

About APUS

Company Profile

APUS logo image Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.

Company Info

APIMEDS PHARMACEUTICALS US I

100 Matawan Road, Suite 325

Matawan NEW JERSEY US

Employees: 2

APUS Company Website

Phone: 18482015010

APIMEDS PHARMACEUTICALS US I / APUS FAQ

What does APIMEDS PHARMACEUTICALS US I do?

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.


What is the stock price of APIMEDS PHARMACEUTICALS US I today?

The current stock price of APUS is 1.23 USD. The price increased by 11.82% in the last trading session.


Does APUS stock pay dividends?

APUS does not pay a dividend.


What is the ChartMill technical and fundamental rating of APUS stock?

APUS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the ownership details for APUS stock?

You can find the ownership structure of APIMEDS PHARMACEUTICALS US I (APUS) on the Ownership tab.